• 作者：M. Belé ; n Ferro-Rey^a ; ^{belen.ferro@pfizer.com} ; Alex Roca-Cusachs^b ; Antoni Sicras-Mainar^c ; Carlos Á ; lvarez-Martí ; n^d ; Marina de Salas-Cansado^e
• 关键词：Combinació ; n fija olmesartan/amlodipino ; Aná ; lisis de impacto presupuestario ; Hipertensió ; n arterial ; Modelo econó ; mico ; Costes farmacoló ; gicos
• 刊名：Atenci贸n Primaria
• 出版年：2011
• 期刊代码：pca69_02126567
• 类别：med
• 出版时间：July 2011
• 卷：43
• 期：7
• 页码：345-355
• 文件大小：254 K

Objective

To carry out a budget impact analysis (BIA) of olmesartan/amlodipine (20/5, 40/5 and 40/10 mg) marketed as a fixed combination (FC) in its approved indication for the National Health System (NHS).

Desig

We developed a decision tree model in order to estimate usual hypertension treatment algorithm in Spanish clinical practice.

Settings

The BIA has been developed from the perspective of the NHS for a period of 3 years (years 2010-2012).

Participants

Spanish hypertensive population 鈮?35 years old.

Interventions

Introduction into the market of a fixed combination (FC) olmesartan/amlodipine in Spain.

Primary measures

Expected costs to be assumed by the Spanish NHS (RRP-VAT) for hypertensive population able to be treated with the FC versus currently assumed costs by the NHS with free combination olmesartan and amlodipine.

Results

Estimated pharmaceutical costs in hypertensive population treated with olmesartan and amlodipine (2 pills) would be 鈧?5.2 M (1^st year), 鈧?6.4 M (2011), 鈧?7.6 M (2012), with a total 3-year period of 鈧?9.2 M. According to patient tree model, the population able to be treated with FC would be 71,283 patients (2010), with a growth rate of 4.8%in the successive years, which supposes an annual cost of 鈧?1.2 M (2010), 鈧?1.8 M (2011) and 鈧?2.4 M (2012), with a total 3-year period of 鈧?5.4 M. The BIA shows savings of 鈧?3.8 M in a total 3-year period.

Conclusion

The BIA of FC olmesartan/amlodipine could generate net savings of 鈧?3.8 M for the NHS in the period ranging from years 2010 to 2012.